Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 141.00
Bid: 140.80
Ask: 141.40
Change: -0.20 (-0.14%)
Spread: 0.60 (0.426%)
Open: 143.40
High: 144.20
Low: 140.60
Prev. Close: 141.20
ELM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Trading Statement

30 Apr 2019 07:00

RNS Number : 4715X
Elementis PLC
30 April 2019
 

Elementis plc

AGM Trading Statement

Market conditions remain challenging, particularly in Coatings

On track to deliver further progress in 2019 led by self-help initiatives

Elementis plc ("Elementis" or the "Group"), a global specialty chemicals company, today issues a trading update for the three months ended 31 March 2019.

Reflecting broader macroeconomic trends, global market conditions remain challenging, particularly in Coatings. Elementis anticipates further progress in 2019, albeit slightly below expectations. Some improvement in the demand environment and further cost efficiencies in-train are expected to result in a stronger second half performance.

The Group remains focused on delivering its plans to integrate the Talc business, transform Coatings and grow Personal Care. This strategy, supported by self-help measures focused on cost efficiency and cash delivery will provide a robust financial platform to deliver future growth and shareholder value creation.

Business performance

· Personal Care had a solid first quarter with strong growth in cosmetics offset by a weaker start in anti-perspirant active ingredients. Bentone HydroclayTM, our new hectorite-based ingredient focused on the skin care market, launched in the quarter and is building encouraging customer momentum.

 

· In Coatings, whilst price/mix improved, weak demand and some de-stocking, particularly in Asia, caused revenue to decline versus the strong prior year period. Early benefits of the transformation programme helped to partially mitigate the profit impact and the programme continues to progress at pace.

 

· Integration of the Talc business remains on track for completion by October 2019 with a focus on delivering $2m of identified cost synergies and new business opportunities. Against strong comparatives, the business saw robust performance across most of its industrial talc applications but weaker demand from paper and automotive markets.

 

· Energy had a steady start to the year with industry infrastructure constraints in North America anticipated to ease in H2.

 

· Chromium sales grew on the prior year period with improved pricing offsetting lower demand levels.

 

Commenting on the performance, CEO, Paul Waterman said,

"Whilst trading conditions in the first quarter of 2019 have proved challenging, Elementis remains focused on delivery, improving returns and deleveraging. This will be underpinned by the integration of the Talc business, delivery of self-help efficiency measures and an unrelenting focus on cash generation."

 

Enquiries

Elementis plc

James Curran, Investor Relations Tel: 020 7067 2994

 

Tulchan

Martin Robinson Tel: 020 7353 4200

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTLLFFTSVIAFIA
Date   Source Headline
12th Apr 202411:33 amRNSDirector/PDMR Shareholding
12th Apr 202411:28 amRNSDirector/PDMR Shareholding
9th Apr 20246:04 pmRNSDirector/PDMR Shareholding
26th Mar 20244:07 pmRNSAnnual Financial Report & Notice of AGM
19th Mar 20243:02 pmRNSAdditional Listing
15th Mar 20241:00 pmRNSDirectorate Change
12th Mar 20244:38 pmRNSDirector/PDMR Shareholding
12th Mar 20244:33 pmRNSDirector/PDMR Shareholding
8th Mar 20245:56 pmRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSDirectorate changes
7th Mar 20247:00 amRNSPreliminary results year ended 31 December 2023
1st Mar 20249:30 amRNSBlock listing Interim Review
18th Jan 20247:00 amRNSTrading Update
2nd Jan 20249:45 amRNSTotal Voting Rights
1st Dec 202310:46 amRNSTotal Voting Rights
30th Nov 20239:38 amRNSDirector/PDMR Shareholding
14th Nov 20237:00 amRNS2023 Capital Markets Day
1st Nov 20239:46 amRNSTotal Voting Rights
31st Oct 20237:00 amRNSThird Quarter Trading Update
2nd Oct 20239:34 amRNSTotal Voting Rights
20th Sep 202312:09 pmRNSResponse to open letter from Franklin Templeton
12th Sep 20233:13 pmRNSDirector Declaration
8th Sep 20239:30 amRNSHolding(s) in Company
1st Sep 20239:49 amRNSBlock listing Interim Review
1st Sep 20239:42 amRNSTotal Voting Rights
1st Aug 20239:44 amRNSTotal Voting Rights
27th Jul 20232:16 pmRNSHolding(s) in Company
27th Jul 20237:00 amRNSHalf-year Report
20th Jul 202312:58 pmRNSHolding(s) in Company
3rd Jul 202310:21 amRNSTotal Voting Rights
29th Jun 20234:29 pmRNSDirector/PDMR Shareholding
23rd Jun 20239:32 amRNSDirector/PDMR Shareholding
30th May 20238:06 amRNSDirector Declaration
2nd May 20239:37 amRNSTotal Voting Rights
26th Apr 20232:12 pmRNSResult of AGM
26th Apr 20237:00 amRNSAGM Trading Statement
17th Apr 202310:15 amRNSDirector/PDMR Shareholding
17th Apr 202310:10 amRNSDirector/PDMR Shareholding
13th Apr 20234:24 pmRNSDirector/PDMR Shareholding
3rd Apr 202311:28 amRNSDirector Declaration
3rd Apr 20239:34 amRNSTotal Voting Rights
24th Mar 20239:27 amRNSDirector/PDMR Shareholding
22nd Mar 20234:02 pmRNSAnnual Financial Report & Notice of AGM
17th Mar 20232:58 pmRNSAdditional Listing
14th Mar 20237:30 amRNSDirector Declaration
9th Mar 20232:50 pmRNSDirector/PDMR Shareholding
9th Mar 20232:47 pmRNSDirector/PDMR Shareholding
7th Mar 20237:00 amRNSPreliminary results year ended 31 December 2022
1st Mar 20239:53 amRNSBlock listing Interim Review
1st Mar 20239:39 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.